<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103596</url>
  </required_header>
  <id_info>
    <org_study_id>P06-124</org_study_id>
    <nct_id>NCT01103596</nct_id>
  </id_info>
  <brief_title>Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)</brief_title>
  <acronym>EOLE</acronym>
  <official_title>Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to ARVs - EOLE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Readitwell</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lincoln Medical and Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate, in patients in at least the second protease
      inhibitor (PI) line, the virological failures under Kaletra® and their consequences on
      protease and reverse transcriptase genotypes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate, in patients in at least the second PI line, the
      virological failures under Kaletra® and their consequences on protease and reverse
      transcriptase genotypes:

        -  Characterisation of the changes in the resistance genotype in protease and reverse
           transcriptase,

        -  Description of the nature and frequency of selected mutations under Kaletra®,

        -  Description of the predictive factors for mutations and of the impact they could have on
           other PIs used as maintenance treatment (analysis based on available algorithms).

      EOLE is a prospective, multicentre observation study offered to French virology laboratories
      and involving clinical teams .

      It is a transversal study with retrospective data collection for patients meeting the study
      criteria (virological failure under Kaletra® after at least first line PI treatment).

      The study comprises two enrolment periods, separated by an interval of one year, over a
      period ranging from 2007 to 2011. During this period, virological failures under Kaletra® are
      identified. For each period, the virologists collect data only from the moment when
      virological failure under Kaletra® is identified.

      The first wave of data collection is now completed and occurred from December 5, 2007 to July
      03, 2009.

      It is not planned to collect follow-up data in connection with alternative treatment with
      other antiretrovirals after failure under Kaletra®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype for resistance determination</measure>
    <time_frame>Over the duration of the enrollment for each wave, over a total period of 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the predictive factors for mutations and of the impact they could have on other protease inhibitors (PIs) used as maintenance treatment (analysis based on available algorithms).</measure>
    <time_frame>Over the duration of the enrollment for each wave, over a total period of 18 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">94</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV-infected patients, 1st wave</arm_group_label>
    <description>HIV-infected ARV-experienced patients treated by a combination including Kaletra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected patients, 2nd wave</arm_group_label>
    <description>HIV-infected ARV-experienced patients treated by a combination including Kaletra</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen plasma for determination of Lopinavir/ritonavir (LPV/r) Cmin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Virology laboratories
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged under 18 years,

          -  Pre-treated by at least one protease inhibitor (PI) line,

          -  In therapeutic failure of the antiretroviral (ARV) maintenance treatment containing
             Kaletra®.

        Therapeutic failure is defined by a viral load&gt; 50 copies/ml after at least three months'
        treatment with an ARV combination containing Kaletra®, always provided that genotyping is
        possible .

        Exclusion Criteria:

          -  Patients having received less than three months of Kaletra®,

          -  Patients for whom the genotype information before starting Kaletra® and at the time of
             the failure of Kaletra® was not available,

          -  Patients receiving another protease inhibitor (PI) concomitantly with Kaletra®.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Cohen Codar, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27801</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27799</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27790</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27796</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27786</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27800</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27798</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27792</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27797</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5595</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27787</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27783</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27802</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27785</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27791</name>
      <address>
        <city>Rennes</city>
        <zip>35700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27788</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27789</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27794</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27784</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>December 13, 2011</last_update_submitted>
  <last_update_submitted_qc>December 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Evaluation of the impact of Kaletra on antiretroviral resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

